HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Provided By GlobeNewswire
Last update: Nov 7, 2024
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024
The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives
Read more at globenewswire.com
